India is among the 52 countries taking part in WHO's Solidarity PLUS trial. This collaboration for Covid-19 research is also studying the e...

The US is still relying on Indian firms to import HCQ even after the drug fell out of favor as a Covid treatment.

The moves by France, Italy and Belgium followed a World Health Organization decision on Monday to pause a large trial of hydroxychloroquine...

The pan-European STOXX 600 index gained 0.2 per cent, after ending Friday with its biggest two-week percentage increase since 2015.

Novartis has reached an agreement with U.S. regulators to hold a randomized trial of generic malaria drug hydroxychloroquine against COVID-...

Novartis AG on Thursday scrapped the $1 billion sale of U.S. generic pill and skin drug assets to India's Aurobindo Pharma Ltd as regulator...

An inexpensive drug widely used since 1955 to treat malaria, Hydroxychloroquine is considered to have relatively harmless side effects. It ...

Other companies including Bayer and Teva have also agreed to donate hydroxychloroquine or similar drugs, while Gilead Sciences is testing i...

Our chief focus for future investments will be: One on increasing our R&D footprint here over time. Second is data and digital.

India remains on Priority Watch List, and continues to be singled out for what the USTR considers to be inadequate protection of intellectu...

Cipla, India’s fifthlargest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug O...

Multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).

The disease is caused by Plasmodium parasites, which are transmitted to humans by the infectious bite of an Anopheles mosquito.

India has been neglecting funding research of diseases such as tuberculosis, malaria, sleeping sickness while funds are poured into honing ...

MNC durgmakers on Wednesday hit back at their domestic counterparts over frivolous patent issue and said even the local firms are engaged i...

Insulin brands, steroids and painkillers may become more expensive once NPPA revises prices of more than 170 medicines, in some cases by as...

Swiss drug maker Novartis says it is lowering the public-sector price of its antimalarial drug Coartem by 20 per cent.